BLU-808 clinical trials
Also written BLU-808.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2024
How each study uses BLU-808 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BLU-808
- 3
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test BLU-808.
- Dec 2026Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)Phase 2 · Blueprint Medicines Corporation
Studies
Open first, then newest update. How each study uses BLU-808 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of BLU-808 in Allergic RhinoconjunctivitisCompletedPhase 2Blueprint Medicines CorporationNCT06922448Written as BLU-808
- Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)Active, not recruitingPhase 2Blueprint Medicines CorporationNCT06931405Written as BLU-808
- Study of BLU-808 in Healthy Adult ParticipantsCompletedPhase 1Blueprint Medicines CorporationNCT06948032Written as BLU-808